Revlimid lenalidomide: Phase III started

Celgene and Groupe d'Etude des Lymphomes de l'Adulte (GELA) began the open-label, international Phase III RELEVANCE trial to compare

Read the full 190 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE